Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes.
In: Immunotherapy Weekly, 2024-06-20, S. 221-221
serialPeriodical
Zugriff:
A recent study analyzed the effectiveness of 177Lu-lilotomab satetraxetan, an anti-CD37 radioimmunoconjugate, in treating lymphoma cell lines. The treatment showed consistent activity in most patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma. The study found that CD37-targeted radioimmunotherapy was more effective in CD37-positive B-cell lymphomas compared to CD37-negative T-cell lymphomas. Additionally, the study identified potential biomarkers and co-targets to detect and overcome cancer cell-intrinsic resistance mechanisms. However, it should be noted that this study has not yet undergone peer review. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes.
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-06-20, S. 221-221 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|